Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07
  • Transmission Dynamics of Carbapenemase Genes in CREC: Guangd

    2026-05-07

    Transmission Dynamics of Carbapenemase Genes in Carbapenem-Resistant Enterobacter cloacae: Insights from Guangdong Hospitals

    Study Background and Research Question

    Carbapenem-resistant Enterobacter cloacae (CREC) has emerged as an urgent clinical and public health concern, ranking among the top three most prevalent carbapenem-resistant Enterobacteriaceae in China (Chen et al., 2025). The COVID-19 pandemic further complicated this landscape, exacerbating antibiotic use and fostering multidrug resistance. Despite the known significance of carbapenemase-encoding genes (CEGs) as the principal drivers of CREC resistance, comprehensive data on their molecular characteristics and transmission, especially under pandemic-related healthcare disruptions, have been limited (internal_article). The present study by Chen et al. addresses these gaps by analyzing the prevalence, localization, and mobility of CEGs in clinical CREC isolates from eight teaching hospitals in Guangdong province, China.

    Key Innovation from the Reference Study

    This research represents one of the most granular, multicenter investigations into the molecular epidemiology and conjugative transfer of CEGs in CREC during the COVID-19 era (Chen et al., 2025). Notably, it distinguishes between chromosomal and plasmid carriage of key resistance genes, quantifies the efficiency of horizontal gene transfer, and correlates these features with clinical and demographic data. The study's use of both molecular and epidemiological methods provides a robust framework for understanding the ongoing evolution and dissemination of multidrug resistance in Gram-negative pathogens.

    Methods and Experimental Design Insights

    Chen et al. analyzed 54 non-duplicate CREC isolates collected between December 2022 and June 2024 from eight tertiary teaching hospitals. The study employed a multi-pronged methodological approach:
    • Genetic Analysis: PCR and variable temperature SDS plasmid elimination differentiated chromosomal from plasmid-borne CEGs.
    • Antimicrobial Susceptibility Testing: Broth microdilution was used to assess resistance profiles across key antibiotics, including imipenem, cefepime, gentamicin, and fluoroquinolones.
    • Plasmid Conjugation: Mating experiments quantified the efficiency of horizontal gene transfer for various CEGs.
    • Molecular Typing: ERIC-PCR and NTSYS software enabled genotypic clustering and detection of epidemiological links.
    • Mobile Genetic Elements (MGE) Analysis: Identification of MGEs such as ISEcp1 provided insight into gene mobility mechanisms.
    This comprehensive design allowed the authors to delineate both the molecular and epidemiological facets of resistance propagation (Chen et al., 2025).

    Protocol Parameters

    • assay | PCR for CEG detection | 85.19% positive rate among CREC isolates | High sensitivity for resistance gene screening in clinical settings | paper
    • assay | Broth microdilution for antibiotic susceptibility | Resistance rates to gentamicin and others significantly higher in CEG-positive CREC | Enables direct comparison of resistance burden | paper
    • assay | Plasmid conjugation | 95.65% CEG transfer success rate | Demonstrates high potential for horizontal dissemination | paper
    • assay | ERIC-PCR genotyping | 17 genotypes identified among 54 isolates | Maps clonal spread and diversity | paper
    • assay | Use of Gentamycin Sulfate in protein synthesis inhibition assays | ≥51.1 mg/mL (water solubility), purity ≥98.00% | Suitable for ribosome function analysis and resistance mechanism studies | product_spec
    • assay | Optimization of aminoglycoside exposure for resistance studies | Use freshly prepared solutions, avoid long-term storage | Maintains reagent integrity and reproducibility | workflow_recommendation

    Core Findings and Why They Matter

    • High Prevalence and Plasmid Localization of blaNDM-1: 33.33% of isolates harbored blaNDM-1 on both chromosomes and plasmids, while 46.30% carried it exclusively on plasmids. This indicates robust horizontal transfer potential and persistent chromosomal reservoirs (Chen et al., 2025).
    • Multidrug Resistance Is Linked to CEG Carriage: CEG-positive CREC strains exhibited significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative strains (Chen et al., 2025).
    • Efficient Horizontal Gene Transfer: Plasmid conjugation experiments revealed a 95.65% success rate for CEG transfer, with the blaNDM-1 and blaIMP genes being particularly mobile. The blaKPC-2 gene, however, did not transfer under these conditions (Chen et al., 2025).
    • Prevalence of Mobile Genetic Elements: Six types of MGEs were identified, with ISEcp1 being the most common (87.04% of isolates). Co-occurrence of multiple MGEs was frequent, likely facilitating rapid evolution and adaptation of resistance determinants (Chen et al., 2025).
    • Epidemiological Patterns: Detection rates were highest among male patients (64.81%), elderly individuals (72.22%), in respiratory medicine (20.37%), and in sputum samples (33.33%), highlighting vulnerable subpopulations and clinical contexts for targeted interventions (Chen et al., 2025).
    These results underscore the threat posed by efficient, plasmid-mediated spread of carbapenemase genes and support the continued surveillance and molecular tracking of resistance determinants, especially in high-risk hospital settings.

    Comparison with Existing Internal Articles

    Recent internal resources reinforce and contextualize the findings of Chen et al. The article "Transmission of Carbapenemase Genes in Enterobacter cloacae in Guangdong Hospitals" provides an overview of the high rates of multidrug resistance and efficient gene transfer in CREC, aligning with the current study's molecular and epidemiological analysis (internal_article). Meanwhile, "Gentamycin Sulfate in Bacterial Protein Synthesis Research" details experimental workflows for characterizing protein synthesis inhibitors and investigating resistance, supporting the use of aminoglycoside antibiotics like Gentamycin Sulfate in similar research models (internal_article). Both internal sources highlight the value of combining molecular genetics with functional assays for dissecting resistance mechanisms and optimizing experimental reproducibility.

    Limitations and Transferability

    While the multicenter design and robust molecular methods strengthen the conclusions, limitations persist:
    • Geographical Scope: All isolates were drawn from Guangdong province, potentially limiting generalizability to other regions with different epidemiological patterns.
    • Temporal Snapshot: The study covers a specific period during the COVID-19 pandemic, and resistance dynamics may evolve as healthcare practices change.
    • Phenotypic-Genotypic Correlations: While PCR and plasmid curing established gene localization, functional expression and fitness costs were not directly assessed.
    • Experimental Transferability: Protocols and findings are highly relevant to researchers using Gram-negative bacterial infection models, ribosome function analysis, or studying antibiotic resistance mechanisms, but may require adaptation for other organisms or settings.

    Research Support Resources

    To facilitate experimental modeling of bacterial protein synthesis inhibition, ribosome function, and antibiotic resistance, researchers can use Gentamycin Sulfate (SKU A2514), a high-purity aminoglycoside antibiotic suitable for studies involving Gram-negative pathogens and resistance gene transmission. For optimized reproducibility in bacterial protein synthesis research, ensure the compound is freshly prepared and stored at -20°C, as recommended (source: product_spec). APExBIO provides this reagent for research use, supporting workflows that parallel those described in the reference study. For detailed stepwise protocols and troubleshooting, see internal guidance at Gentamycin Sulfate in Bacterial Protein Synthesis Research.